Browsing Tag
Takeda
15 posts
Lilly bets $7.8bn on orexin science with Centessa acquisition as neuroscience race intensifies
Eli Lilly agrees to acquire Centessa Pharmaceuticals for $6.3B, gaining orexin sleep drug cleminorexton. Read the full strategic analysis.
AviadoBio opens fourth ASPIRE-FTD cohort as AVB-101 regains full development rights and secures fresh backing from leading dementia foundations
AviadoBio opens the fourth ASPIRE-FTD cohort, regains full AVB-101 rights from Astellas, and secures ADDF backing. Read what it means for FTD gene therapy.
Does Priority Review signal a commercial breakthrough for Protagonist Therapeutics, Inc.?
Takeda and Protagonist secure FDA Priority Review for rusfertide in PV. Explore the strategic, financial, and competitive implications now.
Takeda’s oveporexton Phase 3 trials show broad success in narcolepsy type 1, paving way for 2025 FDA submission
Takeda announces pivotal Phase 3 trial results for oveporexton (TAK-861), showing statistically significant improvements in narcolepsy type 1 symptoms. Regulatory filings planned.
How Protagonist Therapeutics is building a multi‑indication macrocyclic peptide portfolio with icotrokinra and beyond
Protagonist Therapeutics is building a multi-indication oral biologics platform with icotrokinra and rusfertide. Learn how its macrocyclic peptides are redefining therapy.
Salesforce and Takeda partner to transform pharma engagement with AI-driven Life Sciences Cloud platform
Discover how Salesforce and Takeda are redefining pharma engagement using AI-powered Life Sciences Cloud. Learn how data, AI, and patient outcomes align.
Takeda’s FRUZAQLA gains Health Canada approval, offering hope for metastatic colorectal cancer patients
Takeda Canada Inc. has achieved a significant milestone with the Health Canada approval of FRUZAQLA (fruquintinib), a targeted…
Ascentage Pharma receives $100m payment from Takeda under exclusive option agreement
Ascentage Pharma, a leading global biopharmaceutical company specializing in novel therapies for cancer and other serious diseases, has…
Takeda announces positive results for mezagitamab in Phase 2 ITP study
Takeda Pharmaceutical Company Limited has disclosed favorable top-line outcomes from a Phase 2, randomized, double-blind, placebo-controlled trial, assessing…
Takeda’s TAKHZYRO approved by EC for pediatric hereditary angioedema
Takeda has announced a significant advancement in the treatment of Hereditary Angioedema (HAE), with the European Commission’s approval…